{"name":"OncXerna Theraputics, Inc.","slug":"oncxerna-theraputics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Pembrolizumab Injection","genericName":"Pembrolizumab Injection","slug":"pembrolizumab-injection","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Pembrolizumab Injection","genericName":"Pembrolizumab Injection","slug":"pembrolizumab-injection","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxOamt0S2VkT2M0NkdBNzZUdDRZZGoySzZDM2hhZ2ZxZ0wtd1RVaVJPOXByclV4VmZScDMtMERuczdib0hkNFhtcjZiNlZCM1FuWFV4SEdZSjRLV1NENFRxb2J3UjlmZC1zanREZWJvNm5GMFFOcC1FY2Ewb01qMk1qeXlDZVdRNFN5TGJYclpPVS0tV1htZl8xdVlqbkc4dG9sWHlFczRqa2pBT3NaZEZJVmhhMVh3T1JBdEN5Z3NSb2ZPanAweFlxT01HY3ZwTUxKTU9SaWJuR2lnNVE4WVN0QmlyWTFkLWl1V2pqQzB2ZzNQMW9vSktUaHR0cUhZcHlLRkdCd2ZnOTNidldvTk56R2c2VWduaWdvU2FEYVo5Y1ZYel93N2c?oc=5","date":"2026-03-26","type":"pipeline","source":"Barchart.com","summary":"Metastatic Triple-Negative Breast Cancer Market: Strong Growth Potential Across APAC Through 2036, Driven by Innovation and Rising Disease Burden | DelveInsight - Barchart.com","headline":"Metastatic Triple-Negative Breast Cancer Market: Strong Growth Potential Across APAC Through 2036, Driven by Innovation ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPVEZ4NUh1U0xKRUJKTEg5WWVENGtObHF1Ym5XRkJ1eG9waWt6RDA4aWE1ajh1UVFMRnF4WDdQYUwtRTA3TW1UcURCM1p3YlNJYzRQR0pWbDNrd19pR1JFY3V6aVluRXZYRlAzc1NNY0o5OWh6WXh3NzBtaTdPdkgweGJCdWhQNHNqcEZwSE5pVQ?oc=5","date":"2025-07-29","type":"pipeline","source":"finance.yahoo.com","summary":"Bispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and More - finance.yahoo.co","headline":"Bispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Li","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE5EY1VkWE1EODd3cFVWVFQ0STA2aEtqNEJRbTVaZW1qdTJjVUlUZjY0ZV9tV1pZZDhjaWVJTktFaDNydS1nbjctLTlzWDNkYkZyQTJ2YmpGMXJ3bC1nTlIteUNab2JZVFo3QmV2bVhRdVI3aGM?oc=5","date":"2024-09-26","type":"pipeline","source":"Taylor & Francis Online","summary":"Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer - Taylor & Francis Online","headline":"Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}